Akebia Therapeutics, Inc. Announces Presentation Of Phase 2b Data For AKB-6548 In Non-Dialysis Patients With Anemia Related To Chronic Kidney Disease At The 52nd ERA-EDTA Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), announced that data for AKB-6548, a once-daily, oral therapy for the treatment of anemia related to chronic kidney disease (CKD), were presented today at the 2015 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 52nd Congress, which is being held from May 28 – 31, 2015 in London. Pablo E. Pergola, M.D., Ph.D., Director of the Clinical Advancement Center at Renal Associates PA and Clinical Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio, delivered an oral presentation featuring the data from the Phase 2b clinical study of AKB-6548 in non-dialysis CKD patients. A copy of the presentation is available online at www.akebia.com.

Help employers find you! Check out all the jobs and post your resume.

Back to news